Janssen Biotech has decided to terminate a collaboration and license agreement with Geron Corp for experimental cancer drug imetelstat.
News
FDA accepts Allergan’s Vraylar for review
The US Food and Drug Administration has accepted for review an application from Allergan to expand the scope of its antipsychotic Vraylar.
Draft NICE decision rejects Respreeza for incurable, genetic disorder
NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in adults with severe alpha-1-proteinase inhibitor deficiency.
Roche to file entrectinib for ROS-1 positive NSCLC
Roche is planning to file its investigational cancer drug entrectinib following positive results from early and mid-stage trials with patients with ROS1-positive non-small cell lung cancer (NSCLC).
AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC
AstraZeneca says Imfinzi is the first immunotherapy to show significant overall survival in a curative lung cancer treatment setting.
Life expectancy growth stalls for the first time since 1982
Life expectancy in the UK has stopped increasing for the first time since 1982, show new data released by the Office for National Statistics.
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Novartis to shutter Grimsby site amid manufacturing overhaul
Novartis has announced plans to close its manufacturing site in Grimsby, UK, by the end of 2020, among a wider job cull likely to affect more than 2,200 positions in the country and Switzerland.
US clears Verastem’s Copiktra for blood cancers
Verastem Oncology’s Copiktra has been approved in the US for the treatment relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma after at least two prior therapies.
Farxiga cuts hospitalisation for heart failure or CV death, study shows
AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga.
EC clears AZ’ Imfinzi for locally-advanced, unresectable NSCLC
AstraZeneca’s Imfinzi has been approved in Europe for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC).
UK launch for Ferring’s new testosterone replacement therapy
Ferring Pharmaceuticals has launched testosterone replacement therapy Testavan in the UK.
Keapstone satisfies conditions for further £1m investment
Virtual biotech Keapstone Therapeutics is in line for a further £1 million investment from Parkinson’s UK to move forward its innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s.
Novartis to file Lucentis for rare sight condition in premature babies
Novartis has revealed its intent to file anti-VEGF therapy Lucentis for retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness.
EU approves new option for metastatic melanoma
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
